服用华法林对白内障手术安全性的评估  

Safety assessment of phacoemulsification combined with warfarin therapy

作　　者：陈源[1] 徐明[1] 邢茜[1] 陆炯[1] 

机构地区：[1]常熟市第二人民医院眼科,江苏215500

出　　处：《中华眼外伤职业眼病杂志》2017年第8期586-588,共3页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的评估服用华法林（warfarin）对白内障晶状体超声乳化手术安全性的影响。方法排除凝血酶原国际标准化比率（INR）〉3．0的9l例（94眼）分为3组：A组33例（33眼）无心血管疾病史为对照组，B组28例（30眼）为术前暂停服用华法林组，C组30例（31眼）为不停用华法林组。对各组术中、术后眼内出血发生率进行比较。结果各组所有手术均顺利完成，术中及术后均无眼内出血。结论在INR〈3．0情况下，不停用华法林仍可安全施行白内障超声乳化手术。Objective To evaluate the safety of taking warfarin in phacoemulsification surgery for patients with cartaract. Methods The patients of prothronlbin international normalized ratio （INR） 〉 3.0 were ruled out according to the exclusive criteria. Ninty-four eyes of 91 patients were divided into group A, B and C. Group A,33 eyes of 33 cases without history of cardiovascular clisease ware control group; group B,30 eyes of 28 cases were suspended taking warferin before surgery; group C ,31 eyes of 30 cases received surgeries and took warferin continuously. Incidence of intraocular hemorrhages intraoperative and postoperative were compared among three groups. Results All surgeries were successfully performed. No intraocular hemorrhage occurred among three groups during and after operation. Conclusion Phacoemulsification could be safely performed without discontinuing warfarin in the case of prothrombin INR 〈 3. 0.

关 键 词：华法林 白内障 眼内出血 超声乳化术 

分 类 号：R779.66[医药卫生—眼科]